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VERSION 1 - REVIEW 
REVIEWER Elizabeth Boxall  
Consultant Clinical Scientist  
recently etired from HPA Laboratory Birmingham, UK  
 
 
A possible conflict of interest is that I am currently part of the NICE 
hepatitis B guideline development group (as the virologist) and have 
been looking at network analysis work done by the NICE team of 
researchers 
REVIEW RETURNED 10-Jul-2012 
 
THE STUDY Not qualified to comment on the statistical methods 
RESULTS & CONCLUSIONS as I am not sure how the results have been derived - I can't say if 
they are credible or answer the research question. the summary 
conclusions seem obvious and indisputable. 
GENERAL COMMENTS I am returning this paper as I do not feel qualified to review it 
properly - see comments for editor  
 
While I am familiar with chronic hepatitis B and the antiviral 
treatment  
options, the nature of the response to treatment, how it is measured 
and how  
baseline characteristics and length of follow up can influence 
outcome; I am  
struggling to understand this paper and wish to return it to be 
reviewed by a  
health economist or a statistician.  
Observations:  
It opens with a very good description of a network meta-analysis and 
why we need  
them. The problem of comparison of studies carried out by different 
drug  
manufacturers at different times and with different subject variables 
is also  
well laid out. I am aware that network analysis methods are required 
to compare  
and evaluate treatment studies, as studies of new drugs are not 
compared with  
placebo, but with the 'standard of care treatment' - which in studies 
of  
hepatitis B is Lamivudine. I can also appreciate that any drug will 
work 'less  
well' in patients who are sicker or with more advanced disease. 
Hence the need  
to only review papers describing RCTs where patient variables 
should be  
randomised. The problems with meta-analyses is that different 
studies may have a  
different range of patient variables and the hence the need for 
network analysis  
approach to synthesise all possible data.  
This study re-analyses data from 2 RCTs comparing Entecavir and 
Lamivudine in  
HBeAg+ and HBeAg -ve subjects. I can follow the paper as far as 
page 10 of the  
results, then a variable called 'z' is introduced into the data tables, 
without  
definition or explanation. 'z' may be well know to statisticians or 
health  
economists, but as a general reader I have no idea what its 
relevance might be.  
It is not referred to in the text or is its relevance discussed.  
From then on I am lost and not ashamed to admit to it and therefore 
suggest that  
this paper is either, not suitable for a general BMJ readership, or 
requires  
considerable more explanation and revision to be generally 
understandable.  
e.g. in the abstract the primary outcome measures are "Odds 
ratios(OR) at one  
year", the general reader might well stop there and not go any 
further.  
The paper may be more suitable for the Journal of Extreme 
Statistics  
  
 
REVIEWER Andrea Messori, PharmD  
Area Vasta Toscana Centro  
Regional Health Service  
50126 Firenze  
ITALY 
REVIEW RETURNED 13-Jul-2012 
 
GENERAL COMMENTS This article poses a difficult question because two different issues 
have been addressed at the same time.  
 
The objective of this article is in fact two-fold. On the one hand, an 
analysis of treatments for hepatitis B is presented and, on the other, 
a substantial part of the article is focused on the statistical technique 
adopted as well as on the merits of this sophisticated method of 
analysis.  
 
In my view, the paper could benefit from a more explicit declaration 
of its main objective and, in my view, a single primary objective 
should be unequivocally chosen and declared.  
 
In more detail, the choice could be between these two alternatives:  
 
(1) The main objective of this paper is the analysis of the 
effectiveness data of treatments for hepatitis B. Accordingly, the 
statistical approach firstly is described in the Methods section 
without excessive details. In addition, since this statistics is quite 
sophisticated and offers a number of specific clues, an appendix –if 
necessary- could be added at the end of the article in which the 
authors present a more complete description of their statistics.  
 
or  
 
(2) Given that this statistics of indirect comparisons incorporating co-
variates has rarely been applied in the previous literature and can 
therefore be seen as an original finding, the main objective of this 
paper is to offer a thorough examination of this statistical topic. In 
this framework, the case of hepatitis B is presented just as an 
example, and it would probably be useful to add another example to 
better describe the pros and the cons of the statistical approach.  
 
In my view, this paper deals, in either case, with an interesting issue. 
Before suggesting further comments, my preliminary opinion is that, 
in the first place, the paper should be reorganised according to 
either approach, i.e. Approach (1) or Approach (2). Thereafter, I am 
afraid that a further review of the paper is likely to be needed 
particularly if the paper does not perfectly fit, in its second draft, the 
objectives indicated as Objective (1) or Objective (2)  
 
I personally have no specific preference on whether Approach (1) or 
Approach (2) should be given priority.  
 
 
SPECIFIC COMMENTS  
 
In my view, it is premature to offer specific comments because it is 
crucial to know which of the two approaches the authors feel to be 
their priority. 
 
 
 
REVIEWER Gane, Edward 
Auckland City Hospital, New Zealand Liver Unit 
REVIEW RETURNED 26-Sep-2012 
 
REPORTING & ETHICS This paper by Ali et al is a complicated analysis of the predictive 
value of treatment choice and baseline predictors of response in 
CHB. This represents a well designed study. Although the 
methodology of network-meta-analysis (NMA) technique is complex, 
the BMJ Open would seem a suitable forum for this work, to enable 
other researchers in the field of pharmaco-economic modeling, and 
policy generation to digest this analysis.  
However, the following minor issues need to be addressed before 
this paper can be considered acceptable for publication in the BMJ.  
The Authors need to expand the discussion, to include a succinct 
interpretationo f the analyses for the reader with less understanding 
of network-meta-analysis (NMA) techniques. Does this analysis tell 
us that entecavir is more cost effective than lamivudine in all 
scenarios? in more general terms so that it is interpretable by the 
general readership of this journal.  
The Authors do not include either HbeAg seroconversion in HbeAg 
positive CHB, or HBsAg clearance in all CHB as a primary endpoint 
for the analysis.  
The significance of the analysis is limited by the fact that only 2 
antivirals are included. The Authors should include in the Discussion 
whether they would expect different outcomes for agents such as 
adefovir which is less potent than lamivudine (and hence slower 
HBV DNA decline) but higher barrier to resistance? Or tenofovir 
which is as potent as lamivudine but with high barrier to resistance? 
It should be repeated with the inclusion of tenofovir and adefovir.  
What impact doe steh price of the drug have – i.e. is this analysis 
influenced by the country where it is performed?  
In summary, once these issues have been addressed in the revised 
manuscript, then this paper should be suitable for publication in the 
BMJ Open. 
 
REVIEWER Dr Claudia Geue  
Research Associate  
Health Economics and Health Technology Assessment  
University of Glasgow  
United Kingdom 
REVIEW RETURNED 16-Oct-2012 
 
THE STUDY Information on the number of participants in each of the trials would 
be helpful. I notice these are mentioned in the abstract, but the 
authors may want to include these information in the main text.  
 
The authors state in their abstract the 'OR at one year' as their 
primary outcome measure. It is not quite clear how this translates 
into results presented in the main text (48 weeks).  
 
The STROBE checklist supplied as supplementary material does not 
seem to have page numbers assigned to each of the checklist items. 
RESULTS & CONCLUSIONS Perhaps the authors could provide some model fit statistics. When 
describing results a reference to the appropriate table would be 
helpful. 
 
 
VERSION 1 – AUTHOR RESPONSE 
Review 1  
 
Reviewer Comment Author response  
In my view, the paper could benefit from a more explicit declaration of its main objective and, in my 
view, a single primary objective should be unequivocally chosen and declared.  
 
In more detail, the choice could be between these two alternatives:  
>  
(1) The main objective of this paper is the analysis of the effectiveness data of treatments for hepatitis 
B. Accordingly, the statistical approach firstly is described in the Methods section without excessive 
details. In addition, since this statistics is quite sophisticated and offers a number of specific clues, an 
appendix –if necessary- could be added at the end of the article in which the authors present a more 
complete description of their statistics.  
or  
 
(2) Given that this statistics of indirect comparisons incorporating co-variates has rarely been applied 
in the previous literature and can therefore be seen as an original finding, the main objective of this 
paper is to offer a thorough examination of this statistical topic. In this framework, the case of hepatitis 
B is presented just as an example, and it would probably be useful to add another example to better 
describe the pros and the cons of the statistical approach.  
While we are appreciative of the time and effort put in by the reviewers of our manuscript, and thank 
all three for their comments we would respectfully disagree with the key comment from reviewer one.  
 
The purpose of this paper is neither to assess the efficacy of interventions for CHB nor to provide an 
overview of covariate adjustment techniques in NMA. Instead we look to identify and quantify the 
impact of baseline characteristics, in particular baseline disease severity, on the relative efficacy of 
interventions for CHB. Hence, in the language of meta-analysis, we aimed to identify which covariates 
interacted with treatment effect to act as treatment effect modifiers and to quantify the magnitude of 
this interaction effect in CHB treatment. We believe we are the first authors to undertake such an 
analysis in the area of CHB. We have explained this objective on page 6. Some editing has been 
done to clearly explain this.  
 
As such, we believe that the paper is structured in an appropriate manner for the task undertaken.  
 
The journal may be interested to know that the effectiveness data of entecavir vs lamivudine in CHB 
has already published and referenced in the paper – this is the first alternative proposed by reviewer 
1. Regarding the second alternative objective, in our opinion, it is an entirely different paper and one 
that is currently under development by the authors. This second paper utilises the results from the 
manuscript submitted to BMJ Open in order to assess the impact of adjusting for the interaction on all 
CHB treatments. Once complete, we would of course consider submitting to BMJ Open and would be 
happy for reviewer one to provide an external review. The presence of this second paper highlights 
again the importance of the work presented in the current paper as a standalone piece of research 
and also points to impracticalities of trying to do everything in one manuscript.  
 
Finally, as an aside, we note that two of the three reviewers raised no issue with the structure and 
objective of the manuscript under consideration  
In my view, it is premature to offer specific comments because it is crucial to know which of the two 
approaches the authors feel to be their priority. None  
 
 
Reviewer 2  
The Authors need to expand the discussion, to include a succinct interpretation of the analyses for the 
reader with less understanding of network-meta-analysis (NMA) techniques. Does this analysis tell us 
that entecavir is more cost effective than lamivudine in all scenarios? in more general terms so that it 
is interpretable by the general readership of this journal. The reviewer raises an interesting point in 
terms of the impact of covariate adjustment on cost-effectiveness (and hence reimbursement) but this 
is the subject of a future piece of research. The current manuscript represents a statistical analysis of 
patient level data which identifies treatment effect modifiers on the relative efficacy of interventions for 
CHB and as such no statements about cost-effectiveness can be made. However, this analysis will be 
the cornerstone of the forthcoming NMA and the economic model based on the effectiveness data. 
Therefore, we have not provided a detailed discussion of the NMA methods in this paper.  
The Authors do not include either HbeAg seroconversion in HbeAg positive CHB, or HBsAg clearance 
in all CHB as a primary endpoint for the analysis. The reviewer is correct in this observation. We 
focussed solely on undetectable viral load. The identification of treatment effect modifiers on these 
two endpoints would be an interesting piece of research but is beyond the scope of the current 
manuscript. The reason for choosing undetectable viral load is that it is commonly reported in clinical 
trials and has been used in previous NMA of CHB.  
The significance of the analysis is limited by the fact that only 2 antivirals are included. The Authors 
should include in the Discussion whether they would expect different outcomes for agents such as 
adefovir which is less potent than lamivudine (and hence slower HBV DNA decline) but higher barrier 
to resistance? Or tenofovir which is as potent as lamivudine but with high barrier to resistance? It 
should be repeated with the inclusion of tenofovir and adefovir.  
Text amended to highlight the fact that data from only two interventions was available.  
 
We sympathise with the comments made by the reviewer and in an ideal world we would have used 
all available patient level data. Due, however, to the patents for the compounds being held my 
multiple companies, the provision of patient-level data required for such analysis would require 
several research teams to provide confidential data which is highly unlikely to happen due to 
commercial confidentiality.  
 
We have now noted in the paper that the interaction effects observed in this study may not be 
constant across all treatment comparisons.  
What impact does the price of the drug have – i.e. is this analysis influenced by the country where it is 
performed? The paper contains a statistical analysis of clinical trial data and as such issues such as 
drug pricing will not influence the results.  
In summary, once these issues have been addressed in the revised manuscript, then this paper 
should be suitable for publication in the BMJ Open. Noted with thanks.  
 
Reviewer three  
Information on the number of participants in each of the trials would be helpful. I notice these are 
mentioned in the abstract, but the authors may want to include these information in the main text.  
Text amended in line with reviewer comments  
The authors state in their abstract the 'OR at one year' as their primary outcome measure. It is not 
quite clear how this translates into results presented in the main text (48 weeks).  
Text amended in line with reviewer comments. Unit of time now consistent throughout manuscript  
The STROBE checklist supplied as supplementary material does not seem to have page numbers 
assigned to each of the checklist items.  
Page numbers or comments added to all elements of checklist  
When describing results a reference to the appropriate table would be helpful.  
References to tables now clearly identifiable in the text. 
VERSION 2 – REVIEW 
REVIEWER Andrea Messori  
HTA Unit and University of Firenze  
Regional Health Service  
Firenze  
ITALY 
REVIEW RETURNED 29-Nov-2012 
 
REPORTING & ETHICS I initially had some concerns of unclear design and/or redundant 
publication, but the last explanations offered by the authors have 
been quite convicing. 
GENERAL COMMENTS COMMENTS INCLUDED IN MY PREVIOUS REVIEW:  
“In my view, the paper could benefit from a more explicit declaration 
of its main objective and, in my view, a single primary objective 
should be unequivocally chosen and declared. In more detail, the 
choice could be between these two alternatives:  
(1) The main objective of this paper is the analysis of the 
effectiveness data of treatments for hepatitis B. Accordingly, the 
statistical approach firstly is described in the Methods section 
without excessive details. In addition, since this statistics is quite 
sophisticated and offers a number of specific clues, an appendix –if 
necessary- could be added at the end of the article in which the 
authors present a more complete description of their statistics.  
or  
(2) Given that this statistics of indirect comparisons incorporating co-
variates has rarely been applied in the previous literature and can 
therefore be seen as an original finding, the main objective of this 
paper is to offer a thorough examination of this statistical topic. In 
this framework, the case of hepatitis B is presented just as an 
example, and it would probably be useful to add another example to 
better describe the pros and the cons of the statistical approach.”  
 
 
 
RESPONSE BY S. ALI AND CO-WORKERS:  
While we are appreciative of the time and effort put in by the 
reviewers of our manuscript, and thank all three for their comments 
we would respectfully disagree with the key comment from reviewer 
one.  
The purpose of this paper is neither to assess the efficacy of 
interventions for CHB nor to provide an overview of covariate 
adjustment techniques in NMA. Instead we look to identify and 
quantify the impact of baseline characteristics, in particular baseline 
disease severity, on the relative efficacy of interventions for CHB. 
Hence, in the language of meta-analysis, we aimed to identify which 
covariates interacted with treatment effect to act as treatment effect 
modifiers and to quantify the magnitude of this interaction effect in 
CHB treatment. We believe we are the first authors to undertake 
such an analysis in the area of CHB. We have explained this 
objective on page 6. Some editing has been done to clearly explain 
this. As such, we believe that the paper is structured in an 
appropriate manner for the task undertaken.  
The journal may be interested to know that the effectiveness data of 
entecavir vs lamivudine in CHB has already published and 
referenced in the paper – this is the first alternative proposed by 
reviewer 1. Regarding the second alternative objective, in our 
opinion, it is an entirely different paper and one that is currently 
under development by the authors. This second paper utilises the 
results from the manuscript submitted to BMJ Open in order to 
assess the impact of adjusting for the interaction on all CHB 
treatments. Once complete, we would of course consider submitting 
to BMJ Open and would be happy for reviewer one to provide an 
external review. The presence of this second paper highlights again 
the importance of the work presented in the current paper as a 
standalone piece of research and also points to impracticalities of 
trying to do everything in one manuscript.  
Finally, as an aside, we note that two of the three reviewers raised 
no issue with the structure and objective of the manuscript under 
consideration  
 
 
FURTHER COMMENTS BY ANDREA MESSORI (REVIEWER 1):  
The response on this point by the authors poses a number of 
questions. In my previous review, I suggested a quite profound 
revision of this paper to better select a single objective of the study 
(rather than two objectives altogether). This single objective could be 
either the presentation of the original results of the clinical analysis 
(with the methods description confined to a technical appendix) or 
the presentation of a novel method of analysis (that incidentally used 
the clinical data mainly as an example of its application).  
 
The authors stick to their initial choice in that they confirm their 
preference for a paper pursuing the two objectives at the same time. 
They also are honest in indicating that three separate papers could 
be produced from this overall this body of data, namely: a) the first 
clinical paper that has already been published; b) the present paper 
submitted to BMJ Open; c) a future paper that could be specifically 
focused on the original methodology of this type of analysis.  
In my view, whether or not paper (c ) will eventually be considered 
as a duplicate paper presenting again part of the findings already 
published in papers (a) or (b) is outside the purposes of the present 
review. So, I concentrate only on the degree of redundancy between 
paper (a) and paper (b), i.e. the present manuscript.  
 
As regards this latter point, Ali et al. now present a series of quite 
convincing arguments (“…. we look to identify and quantify the 
impact of baseline characteristics, in particular baseline disease 
severity, on the relative efficacy of interventions for CHB. Hence, in 
the language of meta-analysis, we aimed to identify which covariates 
interacted with treatment effect to act as treatment effect modifiers 
and to quantify the magnitude of this interaction effect in CHB 
treatment. We believe we are the first authors to undertake such an 
analysis in the area of CHB. We have explained this objective on 
page 6. Some editing has been done to clearly explain this.”) to 
support the view that the clinical results described in the present 
paper are an original fining that had not been reported in their 
previous article, i.e. in paper (a).  
 
I agree with Ali et al. that, in general, all articles should preferably be 
designed as “a standalone piece of research” and I also agree, to a 
certain extent, on “impracticalities of trying to do everything in one 
manuscript.”  
This is the reason why, given that the issue of redundant publication 
of the clinical data does not seem to apply, the rewording of some 
sentences, in my view, continues to be needed to avoid giving some 
impression that the development of sophisticated NMAs is one of the 
objectives of this study.  
I appreciate that some (minimal) changes on this point have been 
introduced (e.g. on page 6: “The objective of this study is to explore 
and quantify the relationship between treatment effect and patient 
characteristics, in particular baseline disease severity and time of 
response measurement, in predicting response to CHB treatment“). 
A little additional effort in this direction could however be useful.  
 
Finally, the abstract does not report any 95% confidence interval. 
This index could be preferable as opposed to presenting the exact p-
values for the various statistics. 
 
REVIEWER Claudia Geue, PhD  
Research Associate  
University of Glasgow, UK  
 
No competing interest declared. 
REVIEW RETURNED 22-Nov-2012 
 
REPORTING & ETHICS The authors have clearly addressed the issue raised in my last 
review. I recommend acceptance without changes. 
 
VERSION 2 – AUTHOR RESPONSE 
Reviewer Comment Author response 
 In my view, the paper could benefit from a 
more explicit declaration of its main objective 
and, in my view, a single primary objective 
should be unequivocally chosen and 
declared.  
 
 In more detail, the choice could be between 
these two alternatives: 
>  
(1) The main objective of this paper is the 
analysis of the effectiveness data of 
treatments for hepatitis B. Accordingly, the 
statistical approach firstly is described in the 
Methods section without excessive details. In 
addition, since this statistics is quite 
sophisticated and offers a number of specific 
clues, an appendix –if necessary- could be 
added at the end of the article in which the 
authors present a more complete description 
of their statistics. 
 or 
  
(2) Given that this statistics of indirect 
comparisons incorporating co-variates has 
rarely been applied in the previous literature 
and can therefore be seen as an original 
finding, the main objective of this paper is to 
offer a thorough examination of this 
statistical topic. In this framework, the case 
of hepatitis B is presented just as an 
example, and it would probably be useful to 
add another example to better describe the 
pros and the cons of the statistical approach. 
 
While we are appreciative of the time and effort put in 
by the reviewers of our manuscript, and thank all 
three for their comments we would respectfully 
disagree with the key comment from reviewer one.  
 
The purpose of this paper is neither to assess the 
efficacy of interventions for CHB nor to provide an 
overview of covariate adjustment techniques in NMA. 
Instead we look to identify and quantify the impact of 
baseline characteristics, in particular baseline disease 
severity, on the relative efficacy of interventions for 
CHB. Hence, in the language of meta-analysis, we 
aimed to identify which covariates interacted with 
treatment effect to act as treatment effect modifiers 
and to quantify the magnitude of this interaction effect 
in CHB treatment. We believe we are the first authors 
to undertake such an analysis in the area of CHB. We 
have explained this objective on page 6. Some editing 
has been done to clearly explain this. 
 
As such, we believe that the paper is structured in an 
appropriate manner for the task undertaken. 
 
The journal may be interested to know that the 
effectiveness data of entecavir vs lamivudine in CHB 
has already published and referenced in the paper – 
this is the first alternative proposed by reviewer 1. 
Regarding the second alternative objective, in our 
opinion, it is an entirely different paper and one that is 
currently under development by the authors. This 
second paper utilises the results from the manuscript 
submitted to BMJ Open in order to assess the impact 
of adjusting for the interaction on all CHB treatments. 
Once complete, we would of course consider 
submitting to BMJ Open and would be happy for 
reviewer one to provide an external review.  The 
presence of this second paper highlights again the 
importance of the work presented in the current paper 
as a standalone piece of research and also points to 
impracticalities of trying to do everything in one 
manuscript. 
 
Finally, as an aside, we note that two of the three 
reviewers raised no issue with  the structure and 
objective of the manuscript under consideration 
In my view, it is premature to offer specific 
comments because it is crucial to know 
which of the two approaches the authors feel 
to be their priority. 
None 
 
 
Reviewer 2 
The Authors need to expand the discussion, to 
include a succinct interpretation of the analyses 
for the reader with less understanding of 
network-meta-analysis (NMA) techniques. Does 
this analysis tell us that entecavir is more cost 
effective than lamivudine in all scenarios? in 
more general terms so that it is interpretable by 
the general readership of this journal. 
The reviewer raises an interesting point in terms of 
the impact of covariate adjustment on cost-
effectiveness (and hence reimbursement) but this 
is the subject of a future piece of research. The 
current manuscript represents a statistical analysis 
of patient level data which identifies treatment 
effect modifiers on the relative efficacy of 
interventions for CHB and as such no statements 
about cost-effectiveness can be made. However, 
this analysis will be the cornerstone of the 
forthcoming NMA and the economic model based 
on the effectiveness data. Therefore, we have not 
provided a detailed discussion of the NMA 
methods in this paper. 
The Authors do not include either HbeAg 
seroconversion in HbeAg positive CHB, or 
HBsAg clearance in all CHB as a primary 
endpoint for the analysis. 
The reviewer is correct in this observation. We 
focussed solely on undetectable viral load. The 
identification of treatment effect modifiers on these 
two endpoints would be an interesting piece of 
research but is beyond the scope of the current 
manuscript. The reason for choosing undetectable 
viral load is that it is commonly reported in clinical 
trials and has been used in previous NMA of CHB. 
The significance of the analysis is limited by the 
fact that only 2 antivirals are included. The 
Authors should include in the Discussion 
whether they would expect different outcomes 
for agents such as adefovir which is less potent 
than lamivudine (and hence slower HBV DNA 
decline) but higher barrier to resistance? Or 
tenofovir which is as potent as lamivudine but 
with high barrier to resistance? It should be 
repeated with the inclusion of tenofovir and 
adefovir. 
 
Text amended to highlight the fact that data from 
only two interventions was available. 
 
We sympathise with the comments made by the 
reviewer and in an ideal world we would have used 
all available patient level data. Due, however, to 
the patents for the compounds being held my 
multiple companies, the provision of patient-level 
data required for such analysis would require 
several research teams to provide confidential data 
which is highly unlikely to happen due to 
commercial confidentiality. 
 
We have now noted in the paper that the 
interaction effects observed in this study may not 
be constant across all treatment comparisons. 
What impact does the price of the drug have – 
i.e. is this analysis influenced by the country 
where it is performed? 
The paper contains a statistical analysis of clinical 
trial data and as such issues such as drug pricing 
will not influence the results.   
In summary, once these issues have been 
addressed in the revised manuscript, then this 
paper should be suitable for publication in the 
BMJ Open.  
Noted with thanks. 
 
Reviewer three 
Information on the number of participants in each 
of the trials would be helpful. I notice these are 
mentioned in the abstract, but the authors may 
want to include these information in the main 
text. 
 
Text amended in line with reviewer comments 
The authors state in their abstract the 'OR at one 
year' as their primary outcome measure. It is not 
quite clear how this translates into results 
presented in the main text (48 weeks). 
 
Text amended in line with reviewer comments. 
Unit of time now consistent throughout 
manuscript 
The STROBE checklist supplied as 
supplementary material does not seem to have 
page numbers assigned to each of the checklist 
items.  
 
Page numbers or comments added to all 
elements of checklist 
When describing results a reference to the 
appropriate table would be helpful.  
 
References to tables now clearly identifiable in 
the text. 
 
 
